SCHEMBL416747

SCHEMBL416747

CN(Cc1cccc2c1OCC2)C(=O)CCCSc1ccc(O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.35
KDM4C Q9H3R0 1/20 0.33
ALDH1A1 P00352 2/20 0.32
KCNH2 Q12809 2/20 0.32
CCR8 P51685 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
LMNA P02545 2/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.31
KIF11 P52732 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
BCHE P06276 2/20 0.31
ACHE P22303 2/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL412492 0.84 ALDH1A1 (0.38) KDM4CALDH1A1ESR1ESR2LMNA
SCHEMBL419661 0.78 RAB9A (0.43) ALDH1A1KCNH2LMNAMAPTKMT2A
SCHEMBL2483567 0.78 BCHE (0.34) BCHEACHECHRM2CHRM1NPC1
SCHEMBL414300 0.77 BCHE (0.48) ALDH1A1LMNAMAPTKMT2ABCHE
SCHEMBL417441 0.77 CXCR2 (0.40) PARP1ALDH1A1MAPTHTR2ANPC1
SCHEMBL416348 0.77 METAP2 (0.43) ALDH1A1KMT2A
SCHEMBL418204 0.77 BCHE (0.40) ALDH1A1KCNH2LMNAMAPTKMT2A
SCHEMBL415391 0.76 ALDH1A1 (0.40) ALDH1A1KCNH2LMNAKMT2ABCHE
SCHEMBL415110 0.76 TDP1 (0.48) ALDH1A1KMT2ANPC1RAB9A
SCHEMBL413187 0.76 L3MBTL1 (0.41) ALDH1A1KCNH2LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US claimed
EP-2196453-A1 Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents Cellvir (FR) 2010-06-16 EP claimed
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed
EP-2376431-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2011-10-19 EP disclosed
WO-2010066847-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS CELLVIR (FR) 2010-06-17 WO disclosed
EP-2196453-A1 Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents Cellvir (FR) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 PARP1 810/4885KDM4C 1134/4885ALDH1A1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.